商品信息
联系客服
郑重提醒：
无质量问题不接受退换货，下单前请仔细核对信息。
下单后请及时联系客服核对商品价格，订单生效后再付款。
Phoenix Phamaceuticals/Immunomodulatory Peptides Library/105 peptides/L-013
免费咨询热线
4000-520-616
- Contents:
- List of Peptides:
96 well plate(s), where each well contains 1.5 nmol of peptide packaged in 15µg of BSA.(Please inquire for larger peptide quantity) | |
| Download(PDF) |
| Peptide Name | Catelog No. | M.W. | |
|---|---|---|---|
| 1 | Ac2-26 / Lipocortin-1 (2-26) / Annexin-1 (2-26)(Human) | 072-13 | 3089.47 |
| 2 | Ac-PGP /CXCR Ligand | 072-57 | 311.33 |
| 3 | AcSDKP | 070-04 | 487.50 |
| 4 | ACTH (Human) | 001-01 | 4541.16 |
| 5 | Adrenomedullin (Human) | 010-01 | 6028.82 |
| 6 | Alarin(Human) | 026-34 | 2894.29 |
| 7 | Alarin (Rat) | 026-33 | 2820.17 |
| 8 | Antrin /pro-Somatostatin (1-10) / prepro-Somatostatin (25-34) (Porcine) | 060-01 | 1185.63 |
| 9 | prepro-Augurin (133-148) (Human) | 012-24 | 1847.92 |
| 10 | prepro-Augurin(71-107) (Human) | 012-22 | 4800.33 |
| 11 | Beacon (30-73) | 072-51 | 5273.06 |
| 12 | Bombesin | 007-01 | 1620.87 |
| 13 | C19orf10 (32-98) amide / Myeloid-Derived Growth Factor(MYDGF) precursor (32-98) amide (Human) | 056-60 | 7444.17 |
| 14 | Catestatin(Human) | 053-27 | 2326.71 |
| 15 | Catestatin (K388R,A395G,P403L) Variant /prepro-K388R,A395G,P403L Chromogranin A (Rat) | 053-29 | 2483.89 |
| 16 | CGRP (Human) | 015-02 | 3789.35 |
| 17 | CGRP (Rat, Mouse) | 015-09 | 3806.30 |
| 18 | prepro-ChromograninA (65-84) / Chromofungin (Human, Rat, Mouse, Porcine, Bovine) | 053-09 | 2386.87 |
| 19 | Corticotropin Releasing Factor (CRF) (Human, Rat, Mouse,Canine, Feline) | 019-06 | 4757.52 |
| 20 | Cortistatin-14(Rat) | 060-04 | 1723.05 |
| 21 | Cortistatin-17 (Human) | 060-11 | 2151.53 |
| 22 | Cortistatin-29(Human) | 060-12 | 3440.94 |
| 23 | Cortistatin-29 (Rat) | 060-05 | 3542.11 |
| 24 | Defensin 1,beta, synthetic (Human) | 072-53 | 3928.61 |
| 25 | alpha-Defensin 5 / HD5 (Human) | 072-75 | 3581.19 |
| 26 | Defensin 2,beta, synthetic (Human) | 072-48 | 4328.27 |
| 27 | Defensin 3, beta, short form (Human) | 072-45 | 4113.87 |
| 28 | Defensin 8,beta (Mouse) | 072-44 | 3836.60 |
| 29 | Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human) | 072-17 | 3442.10 |
| 30 | Defensin,beta 4 (Human) | 072-41 | 5982.91 |
| 31 | Defensin, beta CBD103 (Canine) | 072-49 | 4160.24 |
| 32 | acetyl-F2L(1-21) / acetyl-Heme-Biding Protein (HBP) (1-21) (Human, Porcine, Canine) | 072-29 | 2478.99 |
| 33 | FGL Peptide | 073-36 | 1631.81 |
| 34 | [Cys0]-FMLP-RelatedReceptor 1 (324-351) (Human) | 001-80 | 2891.16 |
| 35 | Fractalkine (CX3CL1) Chemokine Domain (1-80) /Fractalkine precursor (25-104) (Human) | 026-81 | 9053.82 |
| 36 | Galanin(1-16) (Rat, Porcine) | 026-08 | 1668.87 |
| 37 | Galanin (1-19) (Human) | 026-02 | 1962.98 |
| 38 | prepro-Galanin(1-30) (Human) | 026-03 | 2938.64 |
| 39 | Galanin (Bovine) | 026-19 | 3149.48 |
| 40 | Galanin(Human) | 026-01 | 3157.45 |
| 41 | Galanin (Porcine) | 026-06 | 3210.56 |
| 42 | Galanin(Rat, Mouse) | 026-13 | 3164.49 |
| 43 | Galanin Message Associated Peptide (GMAP) (44-59) /prepro-Galanin (108-123) (Porcine) | 026-12 | 1485.70 |
| 44 | Galanin-LikePeptide (GALP) (Human) | 026-51 | 6500.37 |
| 45 | Galanin-Like Peptide (GALP) (Rat) | 026-52 | 6502.43 |
| 46 | Gastrin I(Human) | 027-04 | 2098.23 |
| 47 | Gastrin Releasing Peptide (GRP) (Human) | 027-07 | 2859.42 |
| 48 | Ghrelin(1-14) (Human) | 031-39 | 1726.93 |
| 49 | Ghrelin (1-5) amide (Human, Rat, Mouse, Bovine, Canine) | 031-41 | 634.56 |
| 50 | [Ser3(Des-Octanoyl)]-Ghrelin(1-5) amide (Human, Rat, Mouse, Bovine, Canine) | 031-42 | 508.10 |
| 51 | Ghrelin (Human) | 031-30 | 3371.92 |
| 52 | Ghrelin(Rat, Mouse) | 031-31 | 3314.00 |
| 53 | [Ser3(Des-Octanoyl)]-Ghrelin (Rat, Mouse) | 031-33 | 3188.64 |
| 54 | GhrelinC-Terminal Hexapeptide (Human, Rat, Mouse, Canine, Feline) | 031-43 | 711.86 |
| 55 | GIP (Human) | 027-02 | 4983.60 |
| 56 | GLP-1(Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) | 028-09 | 4167.02 |
| 57 | Guanylin (Human) | 073-01 | 1458.70 |
| 58 | hSDF-1alpha, synthetic (Human) | 030-21 | 7606.01 |
| 59 | Intermedin / Adrenomedullin-2 (Human) | 010-48 | 5100.80 |
| 60 | LL37 (17-29)/ FK-13 (Human) | 075-31 | 1719.11 |
| 61 | LL37 (Human) | 075-06 | 4493.36 |
| 62 | LHRH / GnRH(Human, Rat, Mouse, Porcine) | 040-02 | 1182.31 |
| 63 | Mitocryptide-1 (MCT-1) (Human) | 005-42 | 2498.91 |
| 64 | Mitocryptide-2(MCT-2) (Human) | 005-44 | 1828.33 |
| 65 | MSH, alpha (Human, Rat, Mouse) | 043-01 | 1664.91 |
| 66 | Nesfatin-1(1-82) (Human) | 003-26 | 9551.86 |
| 67 | Neurokinin A / Neuromedin L / Substance K (Human, Rat,Mouse) | 046-15 | 1132.55 |
| 68 | Neurokinin B/ Neuromedin K (Human, Rat, Mouse) | 046-26 | 1210.44 |
| 69 | Neuromedin N (Porcine) | 046-38 | 745.48 |
| 70 | Neuromedin U(Rat) | 046-41 | 2641.34 |
| 71 | Neuromedin U-23 (Mouse) | 046-65 | 2706.06 |
| 72 | NeuromedinU-25 (Human) | 046-42 | 3080.42 |
| 73 | Neuromedin U-8 (Porcine) | 046-39 | 1110.59 |
| 74 | NeuromedinU-9 (Mouse, Guinea Pig) | 046-37 | 1168.37 |
| 75 | Neuronostatin-13 (Human, Porcine) | 060-50 | 1415.67 |
| 76 | NeuropeptideS (Human) | 005-89 | 2187.51 |
| 77 | Neuropeptide Y (NPY) (Human, Rat, Mouse) | 049-03 | 4271.71 |
| 78 | Neurotensin(Human, Rat, Mouse) | 048-03 | 1671.92 |
| 79 | Orphanin FQ / Nociceptin (Human, Rat, Mouse, Ox) | 021-55 | 1809.06 |
| 80 | PACAP 27amide (Human, Rat, Ovine) | 052-02 | 3147.65 |
| 81 | PACAP-RelatedPeptide (PRP) (Human) | 052-10 | 3144.71 |
| 82 | PACAP-Related Peptide (PRP) (Rat) | 052-11 | 3361.87 |
| 83 | PEDF-34 /prepro-PEDF (44-77) (Human) | 012-52 | 3763.26 |
| 84 | PEDF-44 / prepro-PEDF (78-121) / P78 (Human) | 012-53 | 4680.25 |
| 85 | PeptideHistidine Isoleucine 27 (PHI-27) (Rat) | 064-03 | 3009.58 |
| 86 | Peptide Histidine Methionine 27 (PHM-27) / PeptideHistidine Isoleucine (PHI) (Human) | 064-07 | 2985.46 |
| 87 | Peptide YY(PYY) (3-36) (Human) | 059-02 | 4049.71 |
| 88 | Phoenixin-20 amide (Human, Rat, Mouse, Porcine, Bovine,Canine) | 079-03 | 2178.45 |
| 89 | PR-39 | 075-09 | 4720.73 |
| 90 | Secretin (Human) | 067-03 | 3039.44 |
| 91 | Secretin(Mouse) | 067-04 | 3057.42 |
| 92 | Secretin (Rat) | 067-06 | 3025.59 |
| 93 | Secretoneurin(Rat) | 047-95 | 3652.01 |
| 94 | Somatostatin (Human, Rat, Mouse, Porcine) | 060-03 | 1637.90 |
| 95 | Somatostatin-28(Human, Rat, Mouse, Porcine) | 060-14 | 3150.62 |
| 96 | Substance P (Human, Rat, Mouse) | 061-05 | 1347.65 |
| 97 | ThymosinBeta4 | 070-41 | 4963.55 |
| 98 | Thymus Activity Factor II (TAF-II) (Bovine) | 072-61 | 618.64 |
| 99 | Urocortin(Human) | 019-14 | 4696.31 |
| 100 | Vasoactive Intestinal Peptide (VIP) (Human, Rat, Mouse,Porcine, Ovine) | 064-16 | 3325.80 |
| 101 | MCP-1(65-76) / CCL2 precursor (88-99) (Human) | 033-06 | 1411.5 |
| 102 | SDF-1 gamma isoform precursor / CXCL12 (90-119) (Human,Mouse) | 030-23 | 3620.36 |
| 103 | CXCL4 /Platelet Factor 4 (PF-4) (47-70) (Human) | 045-66 | 2785.44 |
| 104 | CXCL4L1 / Platelet Factor 4 (PF-4) Var (47-70) (Human) | 045-67 | 2827 |
| 105 | CXCL9 / MIG(77-103) (Human) | 045-63 | 3276.93 |
PD-L1/PD-L2 inhibitor, L5B7
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
Understanding mechanisms of late/acquired cancer immunotherapy resistance is critical to improve outcomes; cellular immunotherapy trials offer a means to probe complex tumor-immune interfaces through defined T cell/antigen interactions. We treated two patients with metastatic Merkel cell carcinoma with autologous Merkel cell polyomavirus specific CD8+ T cells and immune-checkpoint inhibitors. In both cases, dramatic remissions were associated with dense infiltration of activated CD8+s into the regressing tumors. However, late relapses developed at 22 and 18 months, respectively. Here we report single cell RNA sequencing identified dynamic transcriptional suppression of the specific HLA genes presenting the targeted viral epitope in the resistant tumor as a consequence of intense CD8-mediated immunologic pressure; this is distinguished from genetic HLA-loss by its reversibility with drugs. Transcriptional suppression of Class I loci may underlie resistance to other immunotherapies, including checkpoint inhibitors, and have implications for the design of improved immunotherapy treatments.Paulson KG, Voillet V, Mcafee MS, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018;9(1):3868.
Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen-presenting cells (APCs), is a major mechanism of tumor immune evasion. PD-1 and PD-L1 blockade antibodies have produced remarkable clinical activities against a subset of cancers. Binding between T cell-intrinsic PD-1 and APC-intrinsic PD-L1 triggers inhibitory signaling to attenuate the T cell response. Here, we report that PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating APCs. Using reconstitution and cell culture assays, we demonstrate that the co-expressed PD-1 binds to PD-L1 in cis. Such interaction inhibits the ability of PD-L1 to bind T cell-intrinsic PD-1 in trans and, in turn, represses canonical PD-L1/PD-1 inhibitory signaling. Selective blockade of tumor-intrinsic PD-1 frees up tumor-intrinsic PD-L1 to inhibit T cell signaling and cytotoxicity. Our study uncovers another dimension of PD-1 regulation, with important therapeutic implications.Zhao Y, Harrison DL, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24(2):379-390.e6.
High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
The inhibitory checkpoint molecule programmed death (PD)-1 plays a vital role in maintaining immune homeostasis upon binding to its ligands, PD-L1 and PD-L2. Several recent studies have demonstrated that soluble PD-1 (sPD-1) can block the interaction between membrane PD-1 and PD-L1 to enhance the antitumor capability of T cells. However, the affinity of natural sPD-1 binding to PD-L1 is too low to permit therapeutic applications. Here, a PD-1 variant with approximately 3000-fold and 70-fold affinity increase to bind PD-L1 and PD-L2, respectively, was generated through directed molecular evolution and phage display technology. Structural analysis showed that mutations at amino acid positions 124 and 132 of PD-1 played major roles in enhancing the affinity of PD-1 binding to its ligands. The high-affinity PD-1mutant could compete with the binding of antibodies specific to PD-L1 or PD-L2 on cancer cells or dendritic cells, and it could enhance the proliferation and IFN-γ release of activated lymphocytes. These features potentially qualify the high-affinity PD-1 variant as a unique candidate for the development of a new class of PD-1 immune-checkpoint blockade therapeutics.Li Y, Liang Z, Tian Y, et al. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2. Cancer Sci. 2018;109(8):2435-2445.
The interaction between PD-1 on T cells and its ligand PD-L1, which is highly expressed on several types of human tumor cells and tumor infiltrating immune cells, restrains the activity of effector T cells against human cancers and chronic virus infections.
Figure from: Cell Rep. 2018 Jul 10;24(2):379-390.e6. doi: 10.1016/j.celrep.2018.06.054.
No References
蚂蚁淘电商平台
ebiomall.com
ebiomall.com
公司简介
蚂蚁淘（www.ebiomall.cn）是中国大陆目前唯一的生物医疗科研用品B2B跨境交易平台，
该平台由多位经验丰富的生物人和IT人负责运营。蚂蚁淘B2B模式是指客户有采购意向后在蚂蚁
淘搜索全球供应信息，找到合适的产品后在蚂蚁淘下单，然后蚂蚁淘的海外买手进行跨境采购、
运输到中国口岸，最后由蚂蚁淘国内团队报关运输给客户...
蚂蚁淘承诺
正品保证： 全球直采 在线追溯
蚂蚁淘所有产品都是自运营的，我们已经跟国外多家厂方建立品牌推广合作关系, 获得对方的支持和授权； 同时客户可以通过订单详情查看到货物从厂方至客户的所有流程， 确保货物的来源； 正规报关，提供13%增值税发票。
及时交付： 限时必达 畅选无忧
蚂蚁淘的运营团队都是有着多年经验的成员，他们熟悉海外采购、仓储物流、报关等环节； 同时通过在线的流程监控，蚂蚁淘的进口速度比传统企业提高了50%以上， 部分产品甚至能做到7-10天到货，即蚂蚁淘的“时必达”服务。
轻松采购： 在线下单 简单省事
蚂蚁淘的价格是真实透明的，并且具有很大的价格优势，不需要繁杂的询价比价； 报价单与合同可以直接在线生成或打印；就像在京东购物一样， 您的鼠标点击几 次即完成在蚂蚁淘的采购，订单详情会告诉您所有进程。
售后申请： 耐心讲解 优质服务
蚂蚁淘提供的产品在使用过程中如因产品质量问题有售后需求时， 您可通过我的订单提交您的“申请售后”， 蚂蚁淘产品顾问会第一时间为您处理， 在售后服务过程中如遇到问题也可致电蚂蚁淘客服热线：4000-520-616。
常见问题
蚂蚁淘所售产品均为正品吗？
蚂蚁淘的创始人兼CEO是钟定松先生，具有十年的从业经验，在业界享有良好的口碑；
Ebiomall是跨境直采平台，我们直接从厂家采购，自己的团队负责国际物流和清关，中间没有第三方，蚂蚁淘承诺所售产品仅为正品，假一罚十。
下单后可以修改订单吗？
未确认状态的订单可以修改，打开“订单详情”页面，点击右上角的“修改订单”即可，若已审核确定，则订单无法修改。
商品几天可以发货？
现货产品付款审核后即可发货,大部分期货产品在3周左右即可到货,提供时必达服务的产品订单审核十天内即可发货。
订单如何取消？
如订单处于未确定状态，进入“我的订单"页面，找到要取消的订单，点击“取消订单”按钮。
可以开发票吗？
本网站所售商品都是正规清关，均开具13%正规发票，发票金额含配送费金额，另有说明的除外。
如何联系商家？
蚂蚁淘任何页面都有在线咨询功能，点击“联系客服”、“咨询”或“在线咨询”按钮，均可咨询蚂蚁淘在线客服人员，
或拨打4000-520-616，除此之外客户可在 联系我们页面找到更多的联系方式。
收到的商品少了/发错了怎么办？
同个订单购买多个商品可能会分为一个以上包裹发出，可能不会同时送达，建议查看订单详情是否是部分发货状态；如未收到，可联系在线客服或者致电4000-520-616。
退换货/维修需要多长时间？
一般情况下，退货处理周期为客户收到产品一个月内（以快递公司显示签收时间为准），包装规格、数量、品种不符，外观毁损、短缺或缺陷，请在收到货24小时内申请退换货；特殊商品以合同条款为准。
商品咨询
▍
品牌分类
▍
官网分类
▍
品牌问答
